Researchers unveiled a ferritin‑based aggregation cell engager (FACE) that acts as a biomimetic bridge between CAR‑T cells and leukemia targets, increasing functional avidity without altering CAR constructs. FACE functions as a scalable culture supplement that binds CD71 on T cells and leukemia cells, strengthening cell–cell contacts and improving tumor clearance in preclinical models. The platform showed dose‑sparing effects and reduced cytokine release in patient‑derived xenografts, and authors emphasized that the approach can be integrated into existing manufacturing workflows. The papers propose an alternative to genetic re‑engineering for overcoming antigen modulation and relapse in hematologic malignancies.